AHA Scientific Sessions 2026 preview covering cardiovascular therapies, clinical outcomes, genetic medicine and AI diagnostics.

AHA Scientific Sessions 2026 Preview: Cardiovascular Outcomes, Emerging Therapies and AI

AHA 2026 at a glance The AHA Scientific Sessions 2026 will highlight…


Lucid Diligence Brief - BioPharma

Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief

Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Profluent-Lilly AI-Designed Recombinase Partnership

Lucid Diligence Brief: Profluent-Lilly AI-Designed Recombinase Partnership…


Cardiovascular

Cardiovascular Weekly News - September 4th 2025

Cardiovascular Update: AI Targets VT, Evolocumab Approved, Wegovy Cuts Heart…


Privacy Preference Center